Literature DB >> 16321764

Rare uterine cancers.

Sheetal Acharya1, Martee L Hensley, Anthony C Montag, Gini F Fleming.   

Abstract

The most common malignant tumour of the uterus is endometrioid endometrial cancer. However, many less common malignant diseases also develop in the uterus, including both carcinomas and sarcomas. Most notable of these tumours are papillary serous carcinomas, clear-cell carcinomas, carcinosarcomas, stromal sarcomas, and leiomyosarcomas. These less common cancers can be aggressive, and account for a greatly disproportionate amount of deaths from uterine cancers. Because they are uncommon, physicians will usually have seen only a few cases, and randomised data to guide treatment often do not exist. This review summarises the epidemiology, clinical characteristics, and prognoses of the less common malignant diseases of the uterus, and presents the information available to guide the clinician about treatment options.

Entities:  

Mesh:

Year:  2005        PMID: 16321764     DOI: 10.1016/S1470-2045(05)70463-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  30 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Authors:  Liancheng Zhu; Salvatore Lopez; Stefania Bellone; Jonathan Black; Emiliano Cocco; Tiffany Zigras; Federica Predolini; Elena Bonazzoli; Beatrice Bussi; Zachary Stuhmer; Carlton L Schwab; Diana P English; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Tumour Biol       Date:  2015-02-11

3.  A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination.

Authors:  Kouichiro Kawano; Kimio Ushijima; Masato Yokomine; Akimasa Fukui; Morio Ijichi; Toshiharu Kamura
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

4.  [Relapsing uterine leiomyosarcoma: report of a case].

Authors:  Youssef Benabdejlil; Mohammed Elmarjany; Abdellah Babahabib; Mehdi Elhassani; Hafsa Chahdi; Jaouad Kouach; Driss Rahali Moussaoui; Mohammed Dehayni
Journal:  Pan Afr Med J       Date:  2014-09-24

5.  [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].

Authors:  L-C Horn; M Dallacker; K Bilek
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

6.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

7.  Primary extrauterine endometrial stromal cell sarcoma: a case and review.

Authors:  Alla Zemlyak; Sonya Hwang; Eva Chalas; Colette R J Pameijer
Journal:  J Gastrointest Cancer       Date:  2009-03-31

Review 8.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

9.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

Review 10.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.